Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.46 |
| ▸ | BRD2 | P25440 | 2/20 | 0.46 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | TPH1 | P17752 | 10/20 | 0.39 |
| ▸ | TPH2 | Q8IWU9 | 10/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19090235 | 0.93 | KMT2A (0.44) | BRD4BRD2BRD3MEN1KMT2A | |
| SCHEMBL21389583 | 0.85 | BRD4 (0.55) | BRD4BRD2BRD3MEN1KMT2A | |
| SCHEMBL21389579 | 0.72 | MEN1 (0.66) | BRD4BRD2BRD3MEN1KMT2A | |
| SCHEMBL21389557 | 0.72 | MEN1 (0.47) | BRD4BRD2BRD3MEN1KMT2A | |
| SCHEMBL21389578 | 0.71 | MEN1 (0.83) | BRD4BRD2BRD3MEN1KMT2A | |
| SCHEMBL21389565 | 0.70 | KMT2A (0.56) | BRD4BRD2BRD3MEN1KMT2A | |
| SCHEMBL21389560 | 0.68 | MEN1 (0.51) | BRD4BRD2BRD3MEN1KMT2A | |
| SCHEMBL23730767 | 0.68 | MEN1 (0.44) | BRD4BRD2BRD3MEN1KMT2A | |
| SCHEMBL21389545 | 0.67 | BRD4 (0.62) | BRD4BRD2BRD3MEN1KMT2A | |
| SCHEMBL21389540 | 0.67 | BRD4 (0.62) | BRD4BRD2BRD3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11225481-B2 | Xanthine derivative inhibitors of BET proteins | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-01-18 | — | — | US | disclosed |
| EP-3397640-B1 | XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS | INST NAT SANTE RECH MED (FR) | 2021-08-04 | — | — | EP | disclosed |
| US-20190292186-A1 | XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292186-A1 | XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS | BET1, BRD4, BRD3 | BRD4 2/4885BRD2 6/4885BRD3 3/4885 |
| US-11225481-B2 | Xanthine derivative inhibitors of BET proteins | BET1, BRD4, BRD3 | BRD4 2/4885BRD2 6/4885BRD3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.